Latest Healthcare News

Archer Materials has secured a three-year strategic deal with IonQ, the global quantum computing leader, gaining access to advanced quantum cloud services and exploring onshore deployment of quantum hardware in Australia.

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.

Enlitic has landed its inaugural Australian Ensight subscription contract with Lumus Imaging, marking a strategic entry into the local SaaS market and expanding its footprint in diagnostic imaging workflows.

Algorae Pharmaceuticals has clinched a multi-year public hospital supply contract with NSW Health, marking a significant commercial milestone. The rollout is set to begin in the fourth quarter of 2026, underpinning the company's growth ambitions in the Australian healthcare market.

Memphasys has locked in a three-year exclusive distribution agreement for its Felix™ sperm separation system in Thailand, targeting a key IVF market with 110 clinics and 20,000–30,000 cycles annually. The deal adds approximately A$430,500 in contracted revenue, lifting South-East Asian minimum contracts to about A$1 million and contributing to FY2026 Felix™ sales now exceeding A$3 million.

Biome Australia has posted a 30% increase in FY26 sales revenue to $23.9 million, driven by strong domestic demand and strategic moves into onshore manufacturing and international markets.

Aroa Biosurgery delivered a breakout FY26 with NZ$104 million revenue, driven by strong Myriad sales and clinical trial success, setting the stage for ambitious FY27 growth.

Sparc Technologies has unveiled SparcESTM, a graphene additive range designed for electrostatic and conductive coatings, aiming to disrupt a $1.65 billion market driven by data centres, semiconductors, and EV battery manufacturing.

Stakk Ltd anticipates its first operating profit in FY2026, driven by a surge in recurring revenue and major contract wins, with FY2027 revenue projected at $21.8 million based on existing agreements.

BCAL Diagnostics has locked in an additional $4.9 million under its existing convertible note facility alongside a $1.4 million R&D tax offset tranche, reinforcing its funding runway into FY2027 for early cancer detection test development.

Clarity Pharmaceuticals will present compelling data at EANM 2026 demonstrating its 64Cu-SAR-bisPSMA imaging agent’s superior detection of prostate cancer recurrence and promising therapeutic results from 67Cu-SAR-bisPSMA in advanced disease.

Lumos Diagnostics has received a A$709,837 cash refund from the Australian Government’s R&D Tax Incentive, bolstering its investment in proprietary point-of-care diagnostic technologies.